

AAD 15: Psoriasis – Appropriate Assessment & Treatment of Severe Psoriasis

- **National Quality Strategy Domain: Clinical Processes and Effectiveness**
- **Meaningful Measure Area: Management of Chronic Conditions**

2023 COLLECTION TYPE:

QCDR MEASURE

MEASURE TYPE:

Intermediate Outcome – High Priority

DESCRIPTION:

Percentage of patients with a diagnosis of severe psoriasis without a documented Body Surface Area (BSA) or a documented BSA greater than 10% for whom phototherapy or an oral systemic or biologic medication was prescribed.

High Priority Measure: Yes

Meaningful Measure Area: Management of Chronic Conditions

Risk-Adjusted: No

Inverse Measure: No

Proportional Measure: Yes

Continuous Variable Measure: No

Ratio Measure: No

Number of performance rates required for measure: 1st Performance Rate

Care Setting: Outpatient Services

INSTRUCTIONS:

This measure is to be submitted a minimum of once per performance period for all patients with a diagnosis of severe psoriasis (BSA of greater than 10%) seen during the performance period. This measure may be reported by eligible physicians and allied professionals who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

Measure Reporting via Registry

ICD-10-CM diagnosis codes, CPT codes or HCPCS codes and patient demographics are used to identify patients who are included in the measure's denominator. The listed numerator options are used to report the numerator of the measure.

The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

DENOMINATOR:

All patients regardless of age with a diagnosis of psoriasis either without a documented BSA or a documented BSA greater than 10%.

Denominator Criteria (Eligible Cases):

All patients, regardless of age

AND

Diagnosis for Psoriasis (ICD-10-CM): L40.0, L40.1, L40.2, L40.3, L40.4, L40.8, L40.9

AND

Body Surface Area: Greater than 10%

AND

Patient encounter during reporting period (CPT and/or CPT with telehealth modifier): 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, , 99242*, 99243*, 99244*, 99245*, GQ, 95, POS 02

DENOMINATOR NOTE: *Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS CQMs.

NUMERATOR:

Patient is prescribed phototherapy or an oral systemic or biologic medication.

In-office phototherapy (CPT): 96900, 96910, 96912, 96913

Numerator Note: If phototherapy is not done in-office by the prescribing physician or allied professional, note in the medical record that the patient was referred to another for phototherapy or it was done in the patient's home.

Examples of Applicable Medications

Brand Name	Generic Name	Mechanism Action/ Type of Systemic	Indication
Stelara	ustekinumab	IL-12 and IL-23 inhibitors	Psoriasis, Psoriatic arthritis
Cosentyx	secukinumab	IL-17 inhibitors	Psoriasis, Psoriatic arthritis
Siliq	brodalumab	IL-17 inhibitors	Psoriasis
Taltz	ixekizumab	IL-17 inhibitors	Psoriasis, Psoriatic arthritis
Tremfya	guselkumab	IL-23 inhibitors	Psoriasis, Psoriatic arthritis
Skyrizi	risankizumab-rzaa	IL-23 inhibitors	Psoriasis
Amjevita	adalimumab-atto	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Cimzia	certolizumab	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Cyltezo	adalimumab-adbm	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Enbrel	etanercept	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Erelzi	etanercept-szss	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Humira	adalimumab	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Inflectra	infliximab-dyyb	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Remicade	infliximab	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Avsola	infliximab-axxq	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Renflexis	infliximab-abda	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Simponi and Simponi Aria	golimumab	TNF-alpha inhibitors	Psoriatic arthritis
Rheumatrex	methotrexate	Blocks dihydrofolate reductase	Psoriasis
Trexall	methotrexate	Blocks dihydrofolate reductase	Psoriasis
Xatmep	methotrexate	Blocks dihydrofolate reductase	Psoriasis
Otrexup	methotrexate	Inhibits dihydrofolic acid reductase	Psoriasis
Rasuvo	methotrexate	Inhibits dihydrofolic acid reductase	Psoriasis
Gengraf	cyclosporine, modified	Blocks lymphocytes (T cells) and lymphokines	Psoriasis
Neoral	cyclosporine, modified	Blocks lymphocytes (T cells) and lymphokines	Psoriasis
Sandimmune	cyclosporine	Blocks lymphocytes (T cells) and lymphokines	Psoriasis
Otezla	apremilast	Blocks phosphodiesterase- 4 (PDE4)	Psoriasis, Psoriatic arthritis
Soriatane	acitretin	Unknown; activates retinoid receptors	Psoriasis

Ilumya	tildrakizumab	Selective (IL)-23p19 inhibitor	Psoriasis
--------	---------------	--------------------------------	-----------

Numerator Options:

Performance Met: Patient is prescribed phototherapy or an oral systemic or biologic medication.

OR

Denominator Exceptions: Patient declines treatment with phototherapy or an oral systemic or biologic medication; patient has contraindication(s) to therapy

OR

Performance not Met: Patient is not prescribed phototherapy or an oral systemic or biologic medication.

RATIONALE:

Psoriasis is a chronic inflammatory disease that affects approximately 7.4 million people in the United States. Based on U.S. National Health and Wellness Survey and U.S. health plan claims data from October 1, 2007, to September 30, 2012, it was shown that 1.7 million experience moderate to severe psoriasis. Of those with moderate to severe disease, approximately 59% are not treated.

This measure aims to decrease disease severity by appropriately treating the severest of psoriasis patients. By assessing for psoriasis severity regularly and prescribing biologics, systemics, or phototherapy for severe patients (BSA of greater than 10%) this will improve overall disease and make symptoms more manageable.

COPYRIGHT:

©American Academy of Dermatology/Association. All rights reserved.

The American Academy of Dermatology and the American Academy of Dermatology Association (collectively AAD/A) own all right, title, and interest in this quality measure. This quality measure is provided solely for the benefit of AAD/A and its members for the purposes specified herein and for other AAD/A purposes. It may not be used by other parties except with prior written approval of the AAD/A.